NVSEF - ARK Genomic Revolution ETF: Value Realization Will Take Time

• ARKG’s Sharpe Ratio and outperformance suggest great stock-picking by the fund manager.
• However, the neutral rating is premised on a long-term time horizon for value realization in view of ARKG’s rich valuation.
• Furthermore, the general market is not unequivocally rising, and entering into higher-volatility ETFs at this stage with rich valuations may not be prudent.
• There also appears to be greater attention focused on “old economy” stocks as markets look forward to a post-pandemic recovery story.

For further details see: